|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Biochemistry, Academic Medical
Center, University of Amsterdam, Amsterdam, The
Netherlands; Department of Pharmaceutics, Utrecht Institute for
Pharmaceutical Sciences, Utrecht University, Utrecht, The
Netherlands; and the Department of Plasma Proteins, CLB
Division, Sanquin Blood Supply Foundation, Amsterdam, The
Netherlands.
The interaction between the endocytic receptor low density
lipoprotein receptor-related protein (LRP) and either coagulation factor IX or its active derivative factor IXa was studied. Purified factor IX was unable to associate with LRP when analyzed by surface plasmon resonance. By contrast, factor XIa-mediated conversion of
factor IX into factor IXa resulted in reversible dose- and calcium-dependent binding to LRP. Active-site blocking of factor IXa
did not affect binding to LRP, whereas LRP binding was efficiently inhibited in the presence of heparin or antibodies against factor IX or
LRP. The factor IXa-LRP interaction could be described by a 2-site
binding model with equilibrium dissociation constants of 27 nmol/L and
69 nmol/L. Consistent with this model, it was observed that factor IXa
binds to 2 different recombinant receptor fragments of LRP (denoted
cluster II and cluster IV) with equilibrium dissociation constants of
227 nmol/L and 53 nmol/L, respectively. The amount of factor IXa
degraded by LRP-deficient cells was 35% lower than by LRP-expressing
cells, demonstrating that LRP contributes to the transport of factor
IXa to the intracellular degradation pathway. Because ligand binding to
LRP is often preceded by binding to proteoglycans, the contribution of
proteoglycans to the catabolism of factor IXa was addressed by
employing proteoglycan-deficient cells. Degradation of factor IXa by
proteoglycan-deficient cells proceeded at a 83% lower rate than
wild-type cells. In conclusion, the data presented here indicate that
both LRP and proteoglycans have the potential to contribute to the
catabolism of factor IXa.
(Blood. 2000;96:3459-3465) Factor IX is a vitamin K-dependent serine protease
precursor protein that, upon activation, participates in the blood
coagulation process.1 The physiologic importance of factor
IX is apparent from the notion that a deficiency or dysfunction is
associated with the severe bleeding disorder hemophilia
B.2 In plasma, factor IX circulates as an inactive,
single-chain polypeptide (Mr
56 000).3 Activation of factor IX is achieved by limited proteolysis, mediated by factor XIa or factor VIIa, resulting in the
active enzyme factor IXa.4,5 Factor IXa
(Mr 46 000) consists of a heavy and a light
chain that are covalently linked. Factor IXa catalyzes the activation
of factor X in a complex that includes Ca++ ions, the
activated protein cofactor factor VIIIa, and a membrane surface,6 all of which are essential for optimal factor X
activation. When assembled into the membrane-bound complex, factor IXa
may also associate with other molecules present at the cellular
surface. In this respect, in vitro binding studies employing arterial
endothelial cells demonstrated the presence of a factor IXa binding
site.7,8 Recently, the matrix protein collagen type IV has
been proposed to serve as an endothelial cell receptor for factor
IXa.9 Factor IXa shares this binding site with its
precursor, the factor IX zymogen.7-9 In vivo clearance
studies have confirmed the presence of a combined binding site for both
factor IX and IXa.10 Interestingly, the same studies
revealed the presence of an alternative site that recognizes factor IXa
but not its precursor. Removal of factor IXa from the circulation, but
not of factor IX, is markedly delayed by preinfusion of
thrombin/antithrombin or trypsin/ LRP (Mr 600 000), also known as the
Various mechanisms have been proposed that describe the interaction
between LRP and its ligands. First, ligands may directly bind from the
circulation to cell surface-exposed LRP, as exemplified by
In the present study, we assessed the binding of factor IX and factor
IXa to LRP. This was examined by surface plasmon resonance (SPR)
employing purified components. Our data reveal that activation of
factor IX into factor IXa results in exposure of a binding site for LRP
that is located outside the exposed active site. Furthermore, we
observed binding of factor IXa to the separate cluster II and cluster
IV fragments of LRP, providing support for a 2-site binding model. In
addition, degradation of factor IXa was studied using LRP-expressing,
LRP-deficient, and proteoglycan-deficient cells. These experiments
indicate that catabolism of factor IXa involves both LRP and
cell-surface proteoglycans.
Materials
Proteins
Protein concentrations Protein was quantified by the method of Bradford31 using human albumin as a standard. Factor IXa and factor IX concentrations were based on activity measurements as described.29SPR analysis Binding studies were performed employing a BIACORE2000 biosensor system, and SPR analysis was done essentially as described.32 LRP or factor IXa was immobilized on a CM5 sensorchip at the indicated densities using the amine-coupling kit as instructed by the supplier. Routinely, a control channel was activated and blocked using the amine-coupling reagents in the absence of protein. Binding to coated channels was corrected for binding to noncoated channels (< 5% of binding to coated channels). For qualitative measurements, SPR analysis was performed in 20-mmol/L HEPES (pH 7.4), 150-mmol/L NaCl, 2-mmol/L CaCl2, and 0.005% (vol/vol) Tween 20 at 25°C with a flow rate of 5 µL/min. For quantitative measurements of factor IXa binding to immobilized LRP, experiments were performed in duplicate at 5 different concentrations (n = 5) of factor IXa or EGR-factor IXa. The concentrations were chosen at an appropriate range (around Kd values), and the proteins were passed at 25°C with a flow rate of 20 µL/min over 3 separate channels with immobilized LRP and over 1 control (noncoated) channel. Quantitative measurements of cluster II and IV binding to immobilized factor IXa were performed in a similar manner as for intact LRP. Regeneration of the surface of the LRP sensorchip and of the factor IXa sensorchip was performed with 100-mmol/L H3PO4 and 10 mmol/L ethylenediaminetetraacetic acid (EDTA), respectively.Analysis of quantitative SPR data For analysis of the association and dissociation curves of the sensorgrams, BIA evaluation software was used (Biacore AB, Uppsala, Sweden). Interaction constants were determined by performing nonlinear global fitting of data corrected for bulk refractive index changes. Data were fitted according to various models available within the BIA evaluation software. A model describing a 1:1 interaction was found to provide the best fit for data regarding the binding of LRP cluster II or IV to immobilized factor IXa. For the binding of factor IXa to immobilized LRP, a model describing the interaction between factor IXa and 2 independent binding sites (heterologous ligand, parallel reactions) was found to provide the best fit of the experimental data. Goodness of the fits was judged from residual plots and statistical parameters employing previously described equations.32 The data were further validated by subjecting them to tests of se lf-consistency.33Factor XIa-mediated factor IX activation Factor IX (3.2 µmol/L) and Factor XIa (16 nmol/L) were incubated at 37°C in 20-mmol/L HEPES (pH 7.4), 150-mmol/L NaCl, 2-mmol/L CaCl2, and 0.005% (vol/vol) Tween 20. At indicated timepoints, aliquots (5 µL) were taken and diluted 10-fold in the same buffer containing 10-mmol/L benzamidine to prevent further activation. Samples were analyzed by SPR using immobilized LRP (13 fmol/mm2 at a flow of 5 µL/min). Simultaneously with SPR samples, aliquots (25 µL) were taken and added to 8 µL of 0.25-mol/L Tris (pH 6.8), 8% (wt/vol) SDS, 40% (vol/vol) glycerol, and 0.04% (wt/vol) bromophenol blue and subjected to electrophoresis on a 7.5% (wt/vol) SDS-polyacrylamide gel. Proteins were visualized by staining with Coomassie blue brilliant.Solid-phase binding assays LRP (75 ng/well) was immobilized onto to microtiter wells in a volume of 50 µL. Remaining binding sites were blocked with 3% (wt/vol) BSA in 20-mmol/L HEPES (pH 7.4), 150-mmol/L NaCl, 5-mmol/L CaCl2, and 0.05% (vol/vol) Tween 20 (HBST) in a volume of 300 µL. Factor IXa (70 nmol/L) was then added for l hour at 37°C in 1% (wt/vol) BSA in HBST in the absence or presence of various components as indicated. After washing the wells 3 times with HBST, wells were incubated for 1 hour at 37°C in 1% (wt/vol) BSA in HBST with the monoclonal anti-factor IX antibody CLB-FIX 14. Bound CLB-FIX 14 was quantified using biotinylated rat antibodies against mouse immunoglobin G chains (CLB Products, Amsterdam, The Netherlands).
Bound complexes were then detected using horseradish peroxidase-labeled streptavidine (Amersham Pharmacia Biotech).
Cellular degradation assays Three derivatives of CHO cells were used in the present study. CHO-K1 (ATCC CCL-61; American Type Culture Collection, Manassas, VA) is a wild-type cell line that constitutively expresses LRP, as do CHO-745 cells (ATCC CRL-2242). The latter cell line, however, is deficient in xylosyltransferase.34 The cell line CHO 13-5-1 (kindly provided by Dr D. J. FitzGerald) is deficient in LRP and has been prepared by toxin-mediated selection of mutagenized CHO-K1 cells.17 Cells were seeded into 24-well plates in DMEM/F12 medium supplemented with 10% (vol/vol) fetal calf serum, 100-U/mL penicillin, and 100-µg/mL streptomycin. The cells were grown to 90% to 100% confluence, which was accomplished in 2 days. Prior to incubation, cultured cells were extensively washed with DMEM/F12 medium. Degradation assays were initiated by adding 200 µL of 125I-labeled factor IXa (40 nmol/L) in DMEM/F12 containing 1% (wt/vol) BSA and 5-mmol/L CaCl2 (assay medium). Cells were washed 3 times with 1 mL of DMEM/F12 medium after 30 minutes of incubation at 37°C to remove nonbound ligand. Subsequently, the incubation was allowed to proceed for 5 hours at 37°C in 200 µL of assay medium. Then, 100-µL aliquots of the conditioned medium were taken to determine the amount of 10% (wt/vol) trichloroacetic acid-soluble factor IXa degradation products. Radioactivity was measured in a Packard counter (Hewlett-Packard,
Amstelveen, The Netherlands). Total ligand degradation was
corrected for the amount of degradation that occurred in control wells
lacking cells.
Binding of factor IXa and factor IX to immobilized LRP Binding of factor IXa and its precursor, factor IX zymogen, to LRP was investigated by SPR analysis using purified components. When 100-nmol/L factor IX zymogen was passed over LRP, virtually no increase of the resonance signal was observed (Figure 1A). Even in the presence of very high concentrations of factor IX (up to 2 µmol/L), no binding could be detected (not shown), demonstrating that factor IX is unable to bind to LRP. In contrast, efficient binding was observed using 100 nmol/L of factor IXa. Upon replacement of factor IXa solution by buffer, the resonance signal gradually declines, indicating that factor IXa dissociates from immobilized LRP and that binding is reversible (Figure 1A). Because the highest resonance signal is detected with the highest density of immobilized LRP (Figure 1A) and the level of the signal is a function of the concentration of the injected factor IXa (Figure 1B), the binding appears to be dose-dependent. These data indicate that factor IXa, but not its inactive precursor, binds to LRP in a reversible and dose-dependent manner.
Effect of factor XIa-mediated factor IX activation on LRP binding To investigate whether an LRP binding site is exposed during factor IX activation, factor IX was incubated in the presence or absence of its activator factor XIa. As expected, incubation of factor IX in the presence of factor XIa resulted in a time-dependent appearance of factor IXa when determined by SDS-PAGE (inset of Figure 2). Samples simultaneously taken were also tested by SPR analysis for the ability to associate with immobilized LRP. As shown in Figure 2, no association could be observed when factor IX was incubated in the absence of factor XIa (referred to as t = 0). In contrast, in the presence of factor XIa, a time-dependent increase in association with LRP appeared. Control experiments did not show binding to LRP of the catalyst factor XIa (data not shown). Apparently, an LRP binding site within factor IX is exposed upon conversion to factor IXa.
Role of the factor IXa catalytic center in LRP interaction Conversion of the zymogen factor IX into its active derivative factor IXa is associated with the exposure of its active-site residues. To examine to what extent the factor IXa active-site residues contribute to LRP binding, the catalytic triad was irreversibly blocked with the inhibitor EGR-chloromethyl ketone, yielding EGR-factor IXa. Subsequently, the binding of EGR-factor IXa to LRP was compared with that of active factor IXa by measuring the association and the dissociation rate constants kon and koff, respectively (Table 1). Binding of either factor IXa or EGR-factor IXa to LRP could be adequately described by employing a 2-site binding model, and similar kon and koff values were obtained for factor IXa and EGR-factor IXa. The resulting Kd values are 27 nmol/L and 26 nmol/L and are 69 nmol/L and 71 nmol/L for factor IXa and EGR-factor IXa, respectively. Thus, both factor IXa and EGR-factor IXa display similar affinity for LRP, suggesting that the binding site for LRP is located outside the catalytic center of factor IXa. These data further indicate the presence of 2 independent binding sites for factor IXa within the LRP molecule. Alternatively, the possibility exists that LRP is heterogenous as a result of the immobilization procedure.
Binding of factor IXa to separate, recombinant receptor fragments Previously, we have demonstrated that 2 different domains of LRP, designated cluster II and cluster IV, encompass the predominant sites for ligand binding.19 Therefore, we used purified, recombinant receptor fragments (cluster I, II, III, and IV) to investigate whether these fragments bind to immobilized factor IXa when tested by SPR analysis. Whereas no binding could be detected to cluster I and cluster III even at very high concentrations (up to 1 µmol/L) of the injected fragments (data not shown), both cluster II and IV bound to factor IXa. The kinetic constants that describe the interactions between factor IXa and either cluster II or IV were determined and are summarized in Table 1. The calculated Kd values were 53 nmol/L and 227 nmol/L for cluster IV and cluster II, respectively. These data are compatible with the view that clusters II and IV represent 2 independent binding sites for factor IXa within LRP.Effect of anti-factor IXa or anti-LRP polyclonal antibodies on the factor IXa-LRP interaction The interaction between factor IXa and LRP was further investigated to address specificity. LRP immobilized onto microtiter wells was incubated with various concentrations of factor IXa, and bound factor IXa was detected using the monoclonal anti-factor IX antibody CLB-FIX 14. Using this approach, a saturable and dose-dependent binding was observed (not shown). Subsequently, binding of factor IXa to LRP was tested in the presence of polyclonal antibodies directed against factor IXa or LRP. As presented in Figure 3, both antibody preparations inhibited binding of factor IXa to LRP. Binding was also found to be impaired in the presence of EDTA (Figure 3). Because similar data were obtained when binding was assessed in the presence of EDTA using SPR analysis (not shown), these data demonstrate that the interaction between factor IXa and LRP is calcium dependent. Binding of factor IXa to LRP was also studied in the presence of another LRP ligand, urokinase. However, urokinase proved unable to interfere in the interaction between LRP and factor IXa (Figure 3). Apparently, factor IXa and urokinase have different binding sites within LRP.
Effect of heparin on the factor IXa-LRP interaction Other studies have established that most LRP ligands bind to heparin, a property that is usually mediated by a series of positively charged amino acid residues.13 Furthermore, binding of these ligands to the receptor is inhibited by heparin, indicating that amino acid residues that constitute the heparin binding site may be involved in LRP binding as well.23,35 Because factor IXa is also a heparin-binding protein, we investigated whether heparin inhibits the binding of factor IXa to LRP by SPR. As expected, efficient factor IXa binding was observed in the absence of heparin (Figure 4). In the presence of increasing concentrations of heparin (both LMW and unfractionated), however, a decrease of the resonance signal was observed. The binding of factor IXa to LRP was fully suppressed in the presence of 100 U/mL of both LMW and unfractionated heparin (Figure 4). In contrast, little if any inhibition was observed in the presence of 100-µg/mL chondroitin sulfate (Figure 4). Similar data were obtained when binding of factor IXa to LRP was tested in the presence of these heparins or chondroitin sulfate in the above-described solid-phase assay (data not shown). These data indicate that the heparin-binding domain of factor IXa may contribute to the interaction with LRP.
Role of LRP and cell-surface proteoglycans in factor IXa degradation by CHO cells To assess whether LRP is involved in mediating transport of factor IXa to the intracellular degradation pathway, cellular degradation of 125I-labeled factor IXa both in LRP-deficient CHO cells17 and in wild-type CHO cells that constitutively express LRP was addressed. As shown in Figure 5, the amount of factor IXa that was degraded by LRP-deficient cells was reduced by approximately 35% compared with wild-type CHO cells. This observation demonstrates that LRP indeed contributes to the transport of factor IXa to the intracellular degradation pathway. It has previously been shown that various LRP ligands may bind to cell-surface proteoglycans prior to transfer and binding to LRP.25-28 Therefore, the role of proteoglycans in cellular degradation of 125I-labeled factor IXa was also analyzed employing xylosyltransferase-deficient CHO cells. This mutant cell line is well suited to establish the role of proteoglycans because xylosyltransferase deficiency results in inability to generate proteoglycans.34 Significantly, the amount of factor IXa that was degraded by proteoglycan-deficient CHO cells was reduced by more than 80% compared with wild-type cells (Figure 5). Taken together, these data strongly suggest that both LRP and cell-surface proteoglycans have the potential to contribute to the catabolism of factor IXa.
An essential step of the coagulation cascade consists of the
activation of factor X by factor IXa in conjunction with the cofactor
factor VIIIa. Consequently, the extent of factor X activation, and
ultimately the amount of thrombin, depends on the regulation of factor
IXa activity. It has been recognized that factor IXa activity may be
controlled by the serine protease inhibitors (serpins) antithrombin and
protease nexin-2 that may form inactive complexes.36,37 Alternatively, the concentration of factor IXa may be determined by a
catabolic pathway that selectively removes factor IXa from the
circulation. In the present study, the contribution of cell surface-associated molecules to the catabolism of factor IXa was investigated. By using purified components, it is demonstrated that
factor IXa binds to LRP in a reversible dose- and calcium-dependent manner (Figures 1 and 3). In contrast, the factor IX zymogen is unable
to associate with LRP, demonstrating that LRP discriminates between the
inactive and active species of factor IX. This is consistent with the
previous observation that administration of competitive LRP ligands to
mice (ie, thrombin/antithrombin or trypsin/ At present, little is known about the in vivo efficiency of factor IXa inhibition by antithrombin or protease nexin-2, but it seems likely that part of the factor IXa molecules that are generated during coagulation are subject to inhibition by these serpins. It would be of relevance, therefore, that such complexes like other enzyme-serpin complexes (eg, thrombin/antithrombin) are removed from the circulation by LRP. Indeed, it has previously been reported by Kounnas and coworkers that LRP is involved in the cellular uptake of factor IXa/protease nexin-2 complexes.25 The interaction between LRP and factor IXa differs in a number of
aspects from LRP interactions with other serine protease-comprising ligands. First, factor IXa binds to LRP as a free enzyme, whereas most
serine proteases interact with LRP exclusively upon formation of a
complex with a serpin or with The transition of factor IX into its activated derivative factor IXa is associated with the exposure of a binding site for LRP (Figure 2). This site is located apart from the catalytic center, because active site-blocked factor IXa (ie, EGR-factor IXa) and active factor IXa bind equally efficiently to LRP (Table 1). Binding of factor IXa to LRP is efficiently inhibited in the presence of heparin (Figure 4). Several mechanisms may explain this observation. First, heparin may interfere with binding of factor IXa to LRP by sterical hindrance. This seems less likely, however, because both unfractionated heparin and LMW heparin appeared to be equally effective in the inhibition of the factor IXa/LRP interaction. Alternatively, a heparin-binding region within factor IXa may be involved in LRP binding. Such heparin-binding regions in other LRP ligands have indeed been reported to be involved in the interaction with LRP.13 It should be mentioned in this respect that factor IX and factor IXa appear to bind heparin in a similar manner,40 yet only factor IXa is able to bind LRP (Figure 1). It seems conceivable, therefore, that the heparin-binding region within factor IXa contributes to LRP binding in an indirect manner. Efficient activation of factor X requires the assembly of factor IXa and its cofactor factor VIII into a membrane-bound complex. Interestingly, we and others have recently identified factor VIII as a ligand for LRP as well.18,41 Thus, both enzyme and cofactor of the same complex may be catabolized by the same receptor. Whether this indicates that LRP is able to bind both ligands simultaneously or promotes dissociation of the complex remains to be investigated. It seems likely, however, that factor VIIIa/factor IXa-mediated factor X activation is modulated when proceeding at membranes enriched in LRP. It is of interest that the amount of factor Xa generated by the factor VIIIa/factor IXa complex at the surface of endothelial cells is markedly increased compared with the amount generated at the surface of monocytes or fibroblast.42 This may be explained by the notion that monocytes and fibroblasts constitutively express LRP at their surface and, consequently, have the ability to remove factor VIII and factor IXa, whereas human umbilical vein endothelial cells lack this receptor.14,43 A common pathway for many LRP-internalized ligands seems to be emerging that involves cell-surface proteoglycans and possibly other accessory proteins. It has been proposed that several ligands bind to cell-surface proteoglycans prior to internalization by LRP.25-28,44-46 The rationale of this event will be sequestering of ligands to locally increase the concentration on the cell surface beyond Kd values and to accelerate the interaction with LRP. Our current data reveal a similar process for the catabolism of factor IXa because degradation of factor IXa proceeds inefficiently by proteoglycan-deficient CHO cells (Figure 5). Furthermore, it should be noted that in CHO cells degradation of factor IXa is only partially (35%) mediated by LRP. This may be explained by the observation that factor IXa binds efficiently to cluster IV but less efficiently to cluster II, resulting in a reduced rate of degradation of factor IXa compared with ligands that bind to both clusters with similar affinity. This slow rate of degradation via LRP would then ultimately lead to a small contribution of LRP in the total factor IXa degradation. Alternatively, another proteoglycan-dependent mechanism may contribute to factor IXa degradation as well. It is possible that ligand transfer may involve other receptors, including the other members of the LDL receptor family, which are known to share ligands with LRP.13 Alternatively, proteoglycans may directly mediate internalization of ligands without the participation of a surface-bound receptor. This has been reported previously for the syndecan family of proteoglycans, which are able to mediate internalization of atherogenic lipoproteins.47
Submitted December 23, 1999; accepted July 18, 2000.
Supported in part by the Netherlands Organization for Scientific Research, Council for Medical Research, Medical Sciences grant 902-26-175 (J.G.N.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Peter J. Lenting, Department of Haematology, University Medical Center Utrecht, G.03.647, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; e-mail: p.j.lenting{at}lab.azu.nl.
1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991;30:10363-10370[Medline] [Order article via Infotrieve]. 2. Sadler JE, Davie EW. Hemophilia A, hemophilia B, and von Willebrand's disease. In: Stamatoyannopoulos G,Nienhuis A, eds. er P, Majerus P, eds. The Molecular Basis of Blood Diseases. Philadelphia, PA: WB Saunders; 1987:575-629. 3. Di Scipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry. 1977;16:698-706[Medline] [Order article via Infotrieve].
4.
Lindquist PA, Fujikawa K, Davie EW.
Activation of bovine factor IX (Christmas factor) by factor XIa (activated plasma thromboplastin antecedent) and a protease from Russell's viper venom.
J Biol Chem.
1978;253:1902-1909 5. Fujikawa K, Legaz ME, Kato H, Davie EW. The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent). Biochemistry. 1974;13:4508-4516[Medline] [Order article via Infotrieve].
6.
Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S.
Surface-dependent reactions of the vitamin K-dependent enzyme complexes.
Blood.
1990;76:1-16 7. Heimark RL, Schwartz SM. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun. 1983;111:723-731[Medline] [Order article via Infotrieve].
8.
Stern DM, Drillings M, Nossel HL, Hurlet-Jensen A, LaGamma KS, Owen J.
Binding of factors IX and IXa to cultured vascular endothelial cells.
Proc Natl Acad Sci U S A.
1983;80:4119-4123
9.
Cheung WF, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW.
Identification of the endothelial cell binding site for factor IX.
Proc Natl Acad Sci U S A.
1996;93:11068-11073 10. Fuchs HE, Trapp HG, Griffith MJ, Roberts HR, Pizzo SV. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse: role of the endothelium and the plasma proteinase inhibitors. J Clin Invest. 1984;73:1696-1703.
11.
Kounnas MZ, Church FC, Argraves WS, Strickland DK.
Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha 1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein.
J Biol Chem.
1996;271:6523-6529 12. Gliemann J. Receptors of the low density lipoprotein (LDL) receptor family in man: multiple functions of the large family members via interaction with complex ligands. Biol Chem. 1998;379:951-964[Medline] [Order article via Infotrieve]. 13. Neels JG, Horn IR, van den Berg BMM, Pannekoek H, van Zonneveld A-J. Ligand-receptor interactions of the low density lipoprotein receptor-related protein, a multi-ligand endocytic receptor. Fibrinolysis Proteolysis. 1998;12:219-240. 14. Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res. 1992;269:375-382[Medline] [Order article via Infotrieve].
15.
Descamps O, Bilheimer D, Herz J.
Insulin stimulates receptor-mediated uptake of apoE-enriched lipoproteins and activated alpha 2-macroglobulin in adipocytes.
J Biol Chem.
1993;268:974-981
16.
Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J.
Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.
Proc Natl Acad Sci U S A.
1992;89:7422-7426
17.
FitzGerald DJ, Fryling CM, Zdanovsky A, et al.
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein [published erratum appears in J Cell Biol. 1995;130:1015].
J Cell Biol.
1995;129:1533-1541
18.
Lenting PJ, Neels JG, van den Berg BMM, et al.
The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein.
J Biol Chem.
1999;274:23734-23739
19.
Neels JG, van den Berg BMM, Lookene A, Olivecrona G, Pannekoek H, van Zonneveld AJ.
The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties.
J Biol Chem.
1999;274:31305-31311 20. Jensen PH, Moestrup SK, Gliemann J. Purification of the human placental alpha 2-macroglobulin receptor. FEBS Lett. 1989;255:275-280[Medline] [Order article via Infotrieve].
21.
Ashcom JD, Tiller SE, Dickerson K, Cravens JL, Argraves WS, Strickland DK.
The human alpha 2-macroglobulin receptor: identification of a 420-kD cell surface glycoprotein specific for the activated conformation of alpha 2-macroglobulin.
J Cell Biol.
1990;110:1041-1048
22.
Kounnas MZ, Henkin J, Argraves WS, Strickland DK.
Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase.
J Biol Chem.
1993;268:21862-21867
23.
Nykjaer A, Petersen CM, Moller B, et al.
Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex: evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
J Biol Chem.
1992;267:14543-14546
24.
Nykjaer A, Kjoller L, Cohen RL, et al.
Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein: evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
J Biol Chem.
1994;269:25668-25676 25. Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995;82:331-340[Medline] [Order article via Infotrieve].
26.
Chappell DA, Fry GL, Waknitz MA, et al.
Lipoprotein lipase induces catabolism of normal triglyceride-rich lipoproteins via the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in vitro. A process facilitated by cell-surface proteoglycans.
J Biol Chem.
1993;268:14168-14175
27.
Warshawsky I, Broze GJ Jr, Schwartz AL.
The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.
Proc Natl Acad Sci U S A.
1994;91:6664-6668
28.
Mikhailenko I, Kounnas MZ, Strickland DK.
Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin: a process facilitated by cell-surface proteoglycans.
J Biol Chem.
1995;270:9543-9549
29.
Lenting PJ, ter Maat H, Clijsters PPFM, et al.
Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme.
J Biol Chem.
1995;270:14884-14890
30.
Lenting PJ, van de Loo JWHP, Donath MJSH, van Mourik JA, Mertens K.
The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.
J Biol Chem.
1996;271:1935-1940 31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254[Medline] [Order article via Infotrieve].
32.
Horn IR, van den Berg BMM, van der Meijden PZ, Pannekoek H, van Zonneveld A-J.
Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein: evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding.
J Biol Chem.
1997;272:13608-13613 33. Schuck P, Minton AP. Kinetic analysis of biosensor data: elementary tests for self-consistency. Trends Biochem Sci. 1996;21:458-460[Medline] [Order article via Infotrieve].
34.
Esko JD, Stewart TE, Taylor WH.
Animal cell mutants defective in glycosaminoglycan biosynthesis.
Proc Natl Acad Sci U S A.
1985;82:3197-3201
35.
Moestrup SK, Gliemann J.
Analysis of ligand recognition by the purified alpha 2-macroglobulin receptor (low density lipoprotein receptor-related protein): evidence that high affinity of alpha 2-macroglobulin-proteinase complex is achieved by binding to adjacent receptors.
J Biol Chem.
1991;266:14011-14017
36.
Bjork I, Jackson CM, Jornvall H, Lavine KK, Nordling K, Salsgiver WJ.
The active site of antithrombin: release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin.
J Biol Chem.
1982;257:2406-2411 37. Schmaier AH, Dahl LD, Rozemuller AJ, et al. Protease nexin-2/amyloid beta protein precursor: a tight-binding inhibitor of coagulation factor IXa. J Clin Invest. 1993;92:2540-2545.
38.
Narita M, Rudolph AE, Miletich JP, Schwartz AL.
The low-density lipoprotein receptor-related protein (LRP) mediates clearance of coagulation factor Xa in vivo.
Blood.
1998;91:555-560
39.
Bu G, Williams S, Strickland DK, Schwartz AL.
Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.
Proc Natl Acad Sci U S A.
1992;89:7427-7431 40. Wojcik EGC. Human blood coagulation factor IX [dissertation]. Leiden, The Netherlands: University of Leiden; 1997:73-87.
41.
Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG.
Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism.
J Biol Chem.
1999;274:37685-37692 42. Brinkman HJ, Mertens K, Holthuis J, Zwart-Huinink LA, Grijm K, van Mourik JA. The activation of human blood coagulation factor X on the surface of endothelial cells: a comparison with various vascular cells, platelets and monocytes. Br J Haematol. 1994;87:332-342[Medline] [Order article via Infotrieve].
43.
Grobmyer SR, Kuo A, Orishimo M, Okada SS, Cines DB, Barnathan ES.
Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells.
J Biol Chem.
1993;268:13291-13300
44.
Shakibaei M, Frevert U.
Dual interaction of the malaria circumsporozoite protein with the low density lipoprotein receptor-related protein (LRP) and heparan sulfate proteoglycans.
J Exp Med.
1996;184:1699-1711
45.
Kounnas MZ, Chappell DA, Wong H, Argraves WS, Strickland DK.
The cellular internalization and degradation of hepatic lipase is mediated by low density lipoprotein receptor-related protein and requires cell surface proteoglycans.
J Biol Chem.
1995;270:9307-9312
46.
Mahley RW, Ji ZS.
Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E.
J Lipid Res.
1999;40:1-16 47. Fuki IV, Kuhn KM, Lomazov IR, et al. The syndecan family of proteoglycans: novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest. 1997;100:1611-1622[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  E. L. Howard, K. C.D. Becker, C. P. Rusconi, and R. C. Becker Factor IXa Inhibitors as Novel Anticoagulants Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 722 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ruiz, D. Kouiavskaia, M. Migliorini, S. Robinson, E. L. Saenko, N. Gorlatova, D. Li, D. Lawrence, B. T. Hyman, K. H. Weisgraber, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor J. Lipid Res., August 1, 2005; 46(8): 1721 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Shayakhmetov, A. Gaggar, S. Ni, Z.-Y. Li, and A. Lieber Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity J. Virol., June 15, 2005; 79(12): 7478 - 7491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Llorente-Cortes and L. Badimon LDL Receptor-Related Protein and the Vascular Wall: Implications for Atherothrombosis Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 497 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Degryse, J. G. Neels, R.-P. Czekay, K. Aertgeerts, Y.-i. Kamikubo, and D. J. Loskutoff The Low Density Lipoprotein Receptor-related Protein Is a Motogenic Receptor for Plasminogen Activator Inhibitor-1 J. Biol. Chem., May 21, 2004; 279(21): 22595 - 22604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bovenschen, J. Herz, J. M. Grimbergen, P. J. Lenting, L. M. Havekes, K. Mertens, and B. J. M. van Vlijmen Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency Blood, May 15, 2003; 101(10): 3933 - 3939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Bovenschen, R. C. Boertjes, G. van Stempvoort, J. Voorberg, P. J. Lenting, A. B. Meijer, and K. Mertens Low Density Lipoprotein Receptor-related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII J. Biol. Chem., March 7, 2003; 278(11): 9370 - 9377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rohlena, J. A. Kolkman, R. C. Boertjes, K. Mertens, and P. J. Lenting Residues Phe342-Asn346 of Activated Coagulation Factor IX Contribute to the Interaction with Low Density Lipoprotein Receptor-related Protein J. Biol. Chem., March 7, 2003; 278(11): 9394 - 9401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J Bowen Haemophilia A and haemophilia B: molecular insights Mol. Pathol., April 1, 2002; 55(2): 127 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D J Bowen Haemophilia A and haemophilia B: molecular insights Mol. Pathol., February 1, 2002; 55(1): 1 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Sarafanov, N. M. Ananyeva, M. Shima, and E. L. Saenko Cell Surface Heparan Sulfate Proteoglycans Participate in Factor VIII Catabolism Mediated by Low Density Lipoprotein Receptor-related Protein J. Biol. Chem., April 6, 2001; 276(15): 11970 - 11979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Westein, C. V. Denis, B. N. Bouma, and P. J. Lenting The alpha -Chains of C4b-binding Protein Mediate Complex Formation with Low Density Lipoprotein Receptor-related Protein J. Biol. Chem., January 18, 2002; 277(4): 2511 - 2516. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
1-protease inhibitor
complexes.
-amyloid precursor protein, lipoprotein lipase, tissue
factor pathway inhibitor, and thrombospondin.
) or fragmin (
) (0-100 U/mL) or 100-µg/mL
chondroitin sulfate (
). Binding is expressed as the percentage of
binding in the absence of competitor and is corrected for nonspecific
binding (< 5%). Data represent the mean ± SD of 3 experiments.
